Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment
Psoriasis, a chronic inflammatory skin condition, affects about 2% of children. A small subset have isolated nail involvement refractory to topical treatment that can be disabling. The development of targeted biologic agents offers safe, effective options for children with moderate-to-severe skin and nail disease. A few are now Food and Drug Administration (FDA)-approved for children.
INTRODUCTIO …
Psoriasis, a chronic inflammatory skin condition, affects about 2% of children. A small subset have isolated nail involvement refractory to topical treatment that can be disabling. The development of targeted biologic agents offers safe, effective options for children with moderate-to-severe skin and nail disease. A few are now Food and Drug Administration (FDA)-approved for children.
INTRODUCTIO … 
Biologics have revolutionized the treatment of psoriasis, and with new entries into the class, PASI90 and 100 have become attainable for many patients. In this installment of our Therapeutic Cheat Sheet series, we’ll cover everything you need to know to start and monitor your patients on IL-17 blocking therapies.
[caption id="attachment_8301" align="alignleft" width="612"] Click image to en … 